Scopus BioPharma's Total Assets for the quarter that ended in Jun. 2023 was $0.50 Mil.
During the past 12 months, Scopus BioPharma's average Total Assets Growth Rate was -73.70% per year.
During the past 3 years, the average Total Assets Growth Rate was -28.60% per year.
During the past 5 years, the average Total Assets Growth Rate was 26.20% per year.
During the past 6 years, Scopus BioPharma's highest 3-Year average Total Assets Growth Rate was 37.20%. The lowest was -28.60%. And the median was 23.20%.
The historical data trend for Scopus BioPharma's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Scopus BioPharma's Total Assets for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scopus BioPharma (OTCPK:SCPS) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Jun. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Scopus BioPharma's Asset Turnover for the quarter that ended in Jun. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Scopus BioPharma Total Assets Related Terms
Thank you for viewing the detailed overview of Scopus BioPharma's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Scopus BioPharma (Scopus BioPharma) Business Description
Scopus BioPharma Inc a biotechnology company focused on developing therapeutics targeting the endocannabinoid system. The endocannabinoid system is comprised of chemical compounds, or cannabinoids, that interact with cannabinoid receptors which are located throughout the body. The company product candidates would utilize synthetically-produced cannabinoids as opposed to plant-derived compounds. Its product candidate comprises CO-sTiRNA, which is a STAT3 inhibitor gene therapy and MRI-1867.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SCPS has been successfully added to your 